- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06467344
Studie for å evaluere ACDN-01 i ABCA4-relatert retinopati (STELLAR)
ACDN-01-001: Åpen, enkelt stigende dosestudie for å evaluere sikkerheten, tolerabiliteten og den foreløpige effekten av subretinal ACDN-01 hos deltakere med ABCA4-relatert retinopati
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This is an open-label, single ascending dose study of ACDN-01 in adult participants with ABCA4-related retinopathy. The study is designed to evaluate the safety, tolerability, and evidence of biological effect of SAD levels (low, medium, and high) of ACDN-01 when delivered subretinally.
Participants will be followed on study for 2 years for the primary safety and preliminary efficacy endpoints, after which they will continue in the study in a 3-year long-term follow-up period, for a total study duration of 5 years.
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
California
-
San Francisco, California, Forente stater, 94158
- University of San Francisco
-
-
Florida
-
Gainesville, Florida, Forente stater, 32607
- Vitreo Retinal Associates
-
Miami, Florida, Forente stater, 33136
- Bascom Palmer Eye Institute
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21218
- Wilmer Eye Institute at John Hopkins
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Massachusetts Eye and Ear
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48105
- University of Michigan Kellogg Eye Center
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45245
- Cincinnati Eye Institute
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- Casey Eye Institute OHSU
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Children's Hospital of Philadelphia
-
-
Texas
-
Dallas, Texas, Forente stater, 75382
- Retina Foundation of the Southwest
-
Houston, Texas, Forente stater, 77401
- Retina Consultants of Texas
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Presence of mutations in the ABCA4 gene
- ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy)
- Area of atrophy located in the macula of the study eye
- BCVA of 20/50 (0.4 logMAR) or worse
Key Exclusion Criteria:
- The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy
- Retinal disease other than ABCA4-related retinopathy
- Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude adherence to the scheduled study visits, safe participation in the study, or affect the results of the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Low dose of ACDN-01
One time low dose of ACDN-01. |
ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection. |
|
Eksperimentell: Mid-dose of ACDN-01
One time mid-dose of ACDN-01. |
ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection. |
|
Eksperimentell: High dose of ACDN-01
One time high dose of ACDN-01. |
ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety and tolerability of ACDN-01 as measured by the number and severity of adverse events and serious adverse events.
Tidsramme: 12 months
|
To evaluate the safety and tolerability of a single dose of ACDN-01 when administered to participants with ABCA4-related retinopathy. |
12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum tolerated dose for subsequent clinical evaluation will be determined by review of all available safety and tolerability data.
Tidsramme: 12 months
|
To determine maximum tolerated dose (MTD) for subsequent clinical evaluation. |
12 months
|
|
To evaluate for evidence of preliminary efficacy based on fundus autofluorescence (FAF).
Tidsramme: 24 months
|
To evaluate for evidence of preliminary efficacy based on change from baseline in the study eye in the area of macular atrophy in mm2 as measured on FAF over 24 months. |
24 months
|
|
To evaluate for evidence of preliminary efficacy based on optical coherence tomography (OCT).
Tidsramme: 24 months
|
To evaluate for evidence of preliminary efficacy based on change from baseline in the study eye in change in thickness in retinal layers as measured on OCT, over 24 months. |
24 months
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To assess for evidence of preliminary efficacy of ACDN-01 based on best corrected visual acuity.
Tidsramme: 24 months
|
Best Corrected Visual Acuity is measured by number of ETDRS letters read in each eye compared to baseline. |
24 months
|
|
To assess for evidence of preliminary efficacy of ACDN-01 based on patient reported outcome measures.
Tidsramme: 24 months
|
Patient-reported outcome measures will be measured by overall and subscale scores on the Michigan Retinal -Degeneration Questionnaire (MRDQ). |
24 months
|
|
To assess for evidence of preliminary efficacy of ACDN-01 based on contrast sensitivity.
Tidsramme: 24 months
|
Contrast sensitivity is measured using qCSF tests and will measure number of letters read and change in AUC (area under curve). |
24 months
|
|
To assess for evidence of preliminary efficacy of ACDN-01 based on contrast sensitivity.
Tidsramme: 24 months
|
Contrast sensitivity is measured using Pelli-Robson tests and will measure number of letters read and change in AUC (area under curve). |
24 months
|
|
To assess for evidence of preliminary efficacy of ACDN-01 based on microperimetry.
Tidsramme: 24 months
|
Retinal sensitivity will be measured by change in the location of detectable points. |
24 months
|
|
To assess for evidence of preliminary efficacy of ACDN-01 based on microperimetry.
Tidsramme: 24 months
|
Retinal sensitivity will be measured by change in the intensity (dB) of detectable points. |
24 months
|
|
To assess for evidence of preliminary efficacy of ACDN-01 based on microperimetry.
Tidsramme: 24 months
|
Retinal sensitivity will be measured by change in the number of detectable points. |
24 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Murray Abramson, MD, PhD, Ascidian Therapeutics
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ACDN-01-001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .